-
CUA 2024丨Dr. Shancheng Ren: “Super Veil Technique” in Extraperitoneal Single-Port Robotic Radical Prostatectomy Meets Patient Needs, Changhai Urology Continues to Tackle AI, Surgical Strategy, and Other Cutting-Edge Challenges
Younger, low-risk prostate cancer patients often prioritize quality of life, particularly urinary control and sexual function, leading to ongoing clinical exploration for treatment strategies that meet these demands. From September 19 to 22, 2024, the 31st Urology Academic Conference was held at the National Convention Center in Tianjin. After the conference, Urology Frontier invited Dr.…
-
CSCO 2024 | Pioneers in Melanoma Care Chart China’s Path to Personalized Therapies
Although melanoma has a relatively low incidence among malignant tumors, its hidden onset and high malignancy make it a formidable disease. In recent years, targeted and immunotherapy treatments for solid tumors have developed rapidly, many of which began with melanoma and later extended to other cancers. However, there are significant biological differences between melanoma in…
-
CSCO 2024 | Pioneering Cellular Therapies and Precision Strategies in Ovarian Cancer
The 2024 CSCO Ovarian Cancer Session covered various topics, including surgical treatment for ovarian cancer, drug therapy for advanced-stage patients, and data from novel drug research. Dr. Lingying Wu from the Cancer Hospital Chinese Academy of Medical Sciences chaired the session, where Dr. Oliver Dorigo from Stanford University delivered a report on “Cellular Therapy for…
-
Dr. Biyun Wang: Early Exploration and Future Prospects of the Novel ADC Drug GQ1005 in HER2-Low Breast Cancer and HER2-Positive Gastric Cancer
At the 2024 ESMO Conference, the Phase 1a/1b study of the novel drug GQ1005, led by Dr. Biyun Wang from Fudan University Shanghai Cancer Center, was showcased as a poster presentation, garnering significant attention. This study not only confirmed the efficacy and safety of GQ1005 in HER2-low breast cancer and HER2-positive gastric cancer but also…
-
ESMO China’s Voice | Dr. Miaoyan Wei: Fruquintinib Combined with AG Regimen Offers Promising Conversion Therapy Strategy for Liver Metastases in PDAC
The 2024 European Society for Medical Oncology (ESMO) Congress took place in Barcelona, Spain, from September 13 to 17. During the event, Dr. Miaoyan Wei from Fudan University Shanghai Cancer Center presented the results of an open-label, single-arm, single-center Phase II clinical trial exploring the use of fruquintinib combined with nab-paclitaxel and gemcitabine (AG) as…
-
WCLC 2024丨Revolutionary Leap in Lung Cancer: NeoCOAST-2 Unveils Groundbreaking Therapies
The 2024 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), is currently in full swing in San Diego, USA. Oncology Frontier invited domestic lung cancer experts to analyze key research data from the conference. This article presents Dr. Shengxiang Ren’s review of the NeoCOAST-2 study…
-
ESMO 2024 Highlights: Game-Changing Lung Cancer Treatment: Nivolumab’s Strides in Resectable NSCLC
The 2024 European Society for Medical Oncology (ESMO) Annual Congress was held from September 13 to 17 in Barcelona, Spain, where multiple advancements in lung cancer research were presented. Dr. Jonathan D. Spicer from the McGill University Health Centre in Montreal, Canada, shared the updated clinical data from the CheckMate 77T study. During the congress,…
-
Dr. Yi-Long Wu Unveils ROS1-Targeted Therapy Breakthroughs at WCLC 2024
The 2024 World Conference on Lung Cancer (WCLC) recently concluded in San Diego, USA. As one of the largest academic conferences in the field of oncology, WCLC presents the latest cutting-edge advancements, covering all aspects of lung cancer research. Dr. Yilong Wu from Guangdong Provincial People’s Hospital served as an expert chair and delivered a…
Connecting Medical Expertise through Media